5
Sep
2019

Vertex’s Bet on T1D, AZ’s Win in T2D CV Outcomes, & FDA Commish Speculation

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Speaker Pelosi’s Envisioned Drug Price Clampdown, Lundbeck’s Move into Migraine, & Diabetes Drug-Device Pairings
10X Pops on IPO Day, Amgen’s KRAS Drug Tantalizes, & Lilly’s RET Drug Impresses
Amgen Antes Up for Otezla, AbbVie Does the Obvious & an siRNA Nails PCSK9
BIO Leaders Defend Immigrants, Sarepta’s Smackdown, Pfizer Bets $500M on NC